Medical Doctor Program year 2022 Reported 2019–2022 Source: CMS Open Payments, 2026 publication

Daniel Pearson

Pulmonary Disease Dayton, OH Medical Doctor

NPI 1962708552 CMS profile 1216334

4881 Sugar Maple Dr, Dayton, OH 45433

Open in the dashboard

General payments

$61,312

68 records reported · program years 2019–2022

Research payments

$0

Paid to them · None reported · program years 2019–2022

Ownership & investment interest

$0

None reported

Through program year 2022, Daniel Pearson of Dayton, OH is reported in the CMS Open Payments database as having received $61,312 across 68 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Pulmonary Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2022 General $24 1
2021 General $1,123 1
2020 General $9,753 11
2019 General $50,412 55

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Daniel Pearson
  • Pulmonary Disease median
  • Middle half of Pulmonary Disease
  • National median

In program year 2025, general payments to Daniel Pearson were reported at $0. Among 8,914 Pulmonary Disease profiles paid that year, the median was $500 and the middle half received between $124 and $1,893.

Show as a table
Year Daniel Pearson Pulmonary Disease median Middle half National median
2019 $50,412 $377 $109–$1,340 $163
2020 $9,753 $230 $56–$907 $114
2021 $1,123 $269 $68–$1,072 $132
2022 $24 $390 $100–$1,457 $149
2023 $0 $419 $114–$1,659 $160
2024 $0 $476 $123–$1,818 $164
2025 $0 $500 $124–$1,893 $169

Breakdown

Who paid General payments · program years 2019–2022
  1. Regeneron Healthcare Solutions, Inc. $40,722 36 payments
  2. Genzyme Corporation $19,710 24 payments
  3. Veran Medical Technologies, Inc. $790 3 payments
  4. Supernus Pharmaceuticals, Inc. $51 3 payments
  5. Pacira Pharmaceuticals Incorporated $24 1 payment
  6. Allergan Inc. $16 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2022
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $55,930 17 payments
  2. Travel and Lodging $2,621 21 payments
  3. Consulting Fee $1,533 2 payments
  4. Food and Beverage $1,228 28 payments
Products named General payments · program years 2019–2022
  1. DUPIXENT Inflammation And Immunology $40,722 36 payments
  2. DUPIXENT Immunology $15,126 20 payments
  3. DUPIXENT Immunology $4,583 4 payments
  4. Spin $790 3 payments
  5. TROKENDI XR $51 3 payments
  6. Exparel $24 1 payment
  7. STRATTICE $16 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 17 billing codes

Paid by Medicare

$39,096

Medicare's payments for the services billed

Medicare patients

123

Average age 75

Services billed

393

71 women, 52 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Heart failure 68%
Ischemic heart disease 59%
Diabetes 57%
Arthritis 53%
Atrial fibrillation 52%
Chronic kidney disease 52%
COPD 46%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

68 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pulmonary Disease in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2022

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record